STRATEC Annual General Meeting approves further dividend increase and conversion in legal form to SE

Birkenfeld, May 30, 2018

At the Annual General Meeting of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard) held today in Pforzheim, the company’s shareholders approved all agenda items submitted for resolution with clear majorities. Around 81.75% of the company’s share capital was represented at the meeting.

STRATEC will be distributing a dividend of €0.80 per share to its shareholders for the successful 2017 financial year (previous year: €0.77 per share). Shareholders will therefore receive a higher dividend for the fourteenth consecutive year since payment of the first dividend in 2004. The distribution total amounts to €9.5 million and will be paid out to shareholders via their depositing banks on June 5, 2018.

Furthermore, shareholders approved the actions of the Board of Management and the Supervisory Board and also approved the planned conversion of STRATEC Biomedical AG into a European Company (Societas Europaea, SE) named STRATEC SE. STRATEC expects this conversion to be entered in the Commercial Register in the second half of the year.

Shareholders also approved the other agenda items with large majorities in each case.

Further information about the Annual General Meeting can be found at www.stratec.com/agm, where details of voting results will also be published.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.
The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

Further information is available from:
STRATEC Biomedical AG
Jan Keppeler, Investor Relations & Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190
ir@stratec.com
www.stratec.com